Frederieke van Duijnhoven is a surgical oncologist at The Netherlands Cancer Institute. She specialises in breast and thyroid cancer.
Her research focuses on de-escalation of local treatment, both following neoadjuvant systemic therapy and in patients with Ductal Carcinoma in Situ. She was one of the co-PIs in the MICRA trial, in which the accuracy of post-NST biopsies to detect pathologic complete response was assessed. She is a co-PI of the ongoing LORD trial, in which local treatment in patients with DCIS grade I or II is omitted as the majority of these lesions will not evolve into invasive carcinoma.
Since 2019 she is Secretary of the EORTC Breast Cancer Group and a member of the Working group for locoregional therapy. In collaboration with the Imaging Group of the EORTC, studies into the diagnostics and treatment of oligometastatic disease are being developed.